Andrew H. Ko
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Renal cell carcinoma treatment
Most-Cited Works
- → Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy(2011)1,962 cited
- → Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer(2018)1,796 cited
- → Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer(2021)1,676 cited
- → Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology(2021)1,222 cited
- → Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer(2020)1,097 cited
- → Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology(2017)1,021 cited
- → Pancreatic Adenocarcinoma, Version 2.2014(2014)470 cited
- → Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline(2016)373 cited
- → Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019(2019)366 cited
- → Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial(2022)325 cited